{
  "abstract": "Background & Aims: First-line nivolumab demonstrated a higher objective response rate (ORR) and favorable safety profile vs. sorafenib in advanced HCC in the phase III CheckMate 459 trial; however, no significant improvement in overall survival (OS) was observed. Here, we report exploratory biomarker analyses from CheckMate 459.\n\nMethods: Archival or fresh tumor samples were collected before treatment and subjected to whole-exome sequencing, whole-transcriptome RNA sequencing, immunohistochemistry, and serological testing. Biomarkers were examined for associations with clinical outcomes (ORR by blinded independent central review [BICR] per RECIST v1.1, progression-free survival [PFS] by BICR, and OS).\n\nResults: The minimum follow-up was 33.6 months. In the nivolumab arm, 201, 230, 343, and ≥293 patients were evaluable by whole-exome sequencing, RNA sequencing, immunohistochemistry, and serology, respectively; 199, 239, 334, and ≥279 patients were evaluable in the sorafenib arm, respectively. Baseline tumor mutational burden was not predictive of survival with nivolumab. OS with sorafenib was improved in patients with mutated vs. wild-type Wnt/β-catenin pathway; consequently, OS was improved with nivolumab vs. sorafenib in patients with unaltered Wnt/β-catenin pathway (hazard ratio [HR] 0.66; 95% CI 0.47-0.91). High T-cell inflammation gene signature score and tumors with high programmed death ligand 1 levels (combined positive score ≥10) were associated with improved OS with nivolumab vs. sorafenib (HR 0.68; 95% CI 0.47-0.98 and HR 0.55; 95% CI 0.33-0.93, respectively); PFS and ORR were also improved. Among circulating blood biomarkers, high interferon-γ, low pro-collagen 11, and low frequency of granulocytic myeloid-derived suppressor cells were associated with improved nivolumab efficacy vs. sorafenib.\n\nConclusions: These exploratory analyses from CheckMate 459 identified several candidate biomarkers that may be associated with the efficacy of first-line nivolumab vs. sorafenib and support further studies to identify patients with advanced HCC who may benefit from programmed death 1 inhibition.\n\nImpact and implications: Nivolumab demonstrated a higher objective response rate and favorable safety profile as first-line treatment compared with sorafenib for patients with advanced HCC in the CheckMate 459 trial, yet did not show a significant improvement in overall survival. The exploratory analyses presented here have identified several candidate biomarkers that may be associated with the efficacy of nivolumab vs. sorafenib in the first-line setting. These findings support additional studies to identify patients who may benefit from programmed death 1 inhibition.\n\nClinical trial number: NCT02576509.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Translational Medicine, Bristol Myers Squibb, Princeton, NJ, USA",
    "Department of Translational Bioinformatics, Bristol Myers Squibb, Princeton, NJ, USA",
    "Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan",
    "Department of Medicine, Geffen School of Medicine, University of California–Los Angeles, Los Angeles, CA, USA",
    "Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain",
    "Department of Immunology and Immunotherapy, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain",
    "University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA",
    "Department of Medicine, University of Hong Kong, Hong Kong, China",
    "Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA",
    "Centre Hépato-Biliaire, Hôpital Paul Brousse, Assistance Publique Hôpitaux de Paris, Université Saclay and Sorbonne Université, Paris, France",
    "Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA",
    "UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Jaclyn Neely"
    },
    {
      "affs": [
        1
      ],
      "name": "Jin Yao"
    },
    {
      "affs": [
        2
      ],
      "name": "Masatoshi Kudo"
    },
    {
      "affs": [
        3
      ],
      "name": "Richard S. Finn"
    },
    {
      "affs": [
        4
      ],
      "name": "Bruno Sangro"
    },
    {
      "affs": [
        5
      ],
      "name": "Ignacio Melero"
    },
    {
      "affs": [
        6
      ],
      "name": "Anthony B. El-Khoueiry"
    },
    {
      "affs": [
        7
      ],
      "name": "Thomas Yau"
    },
    {
      "affs": [
        8
      ],
      "name": "James J. Harding"
    },
    {
      "affs": [
        9
      ],
      "name": "Olivier Rosmorduc"
    },
    {
      "affs": [
        10
      ],
      "name": "Marina Tschaika"
    },
    {
      "affs": [
        0
      ],
      "name": "Ruslan Novosiadly"
    },
    {
      "affs": [
        0
      ],
      "name": "Amanda Cruz"
    },
    {
      "affs": [
        11
      ],
      "name": "Robin Kate Kelley"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e1z5jnfjgkzzj.bib",
  "cited_by": 0,
  "doi": "10.1016/j.jhepr.2026.102038",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13744911/",
  "id": "e1z5jnfjgkzzj",
  "issns": [
    "2589-5559"
  ],
  "landing_url": "https://doi.org/10.1016/j.jhepr.2026.102038",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2721|Hepatocellular Carcinoma Treatment and Prognosis"
    ]
  ],
  "openalex": "W7213627611",
  "pdf_url": "https://www.jhep-reports.eu/article/S2589-5559(26)00309-5/pdf",
  "pmcid": "PMC13744911",
  "pmid": "42762856",
  "published": "2026-09-19",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/e1z5jnfjgkzzj.ris",
  "sources": [
    {
      "first_seen": "2026-11-11T12:22:22Z",
      "native_id": "PMC13744911",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.jhepr.2026.102038"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2721|Hepatocellular Carcinoma Treatment and Prognosis",
      "subfield": "general"
    }
  ],
  "title": "Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial",
  "title_text": "Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: Results from the CheckMate 459 phase III trial",
  "type": "peer-reviewed",
  "updated_at": "2026-11-12T12:21:19Z",
  "url": "https://research.draconitic.com/paper/e1z5jnfjgkzzj",
  "venue": "JHEP Reports",
  "versions": []
}